Literature DB >> 24596271

Onset of hippocampus-dependent memory impairments in 5XFAD transgenic mouse model of Alzheimer's disease.

Stéphane D Girard1, Marlyse Jacquet, Kévin Baranger, Martine Migliorati, Guy Escoffier, Anne Bernard, Michel Khrestchatisky, François Féron, Santiago Rivera, François S Roman, Evelyne Marchetti.   

Abstract

The 5XFAD mice are an early-onset transgenic model of Alzheimer's disease (AD) in which amyloid plaques are first observed between two and four months of age in the cortical layer five and in the subiculum of the hippocampal formation. Although cognitive alterations have been described in these mice, there are no studies that focused on the onset of hippocampus-dependent memory deficits, which are a hallmark of the prodromal stage of AD. To identify when the first learning and memory impairments appear, 5XFAD mice of two, four, and six months of age were compared with their respective wild-type littermates using the olfactory tubing maze, which is a very sensitive hippocampal-dependent task. Deficits in learning and memory started at four months with a substantial increase at six months of age while no olfactory impairments were observed. The volumetric study using magnetic resonance imaging of the whole brain and specific areas (olfactory bulb, striatum, and hippocampus) did not reveal neuro-anatomical difference. Slight memory deficits appeared at 4 months of age in correlation with an increased astrogliosis and amyloid plaque formation. This early impairment in learning and memory related to the hippocampal dysfunction is particularly suited to assess preclinical therapeutic strategies aiming to delay or suppress the onset of AD.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  amyloid plaques; behavioral assessment; gliosis; hippocampus; olfactory tubing maze

Mesh:

Substances:

Year:  2014        PMID: 24596271     DOI: 10.1002/hipo.22267

Source DB:  PubMed          Journal:  Hippocampus        ISSN: 1050-9631            Impact factor:   3.899


  38 in total

1.  5XFAD mice show early-onset gap encoding deficits in the auditory cortex.

Authors:  Aldis P Weible; Amanda J Stebritz; Michael Wehr
Journal:  Neurobiol Aging       Date:  2020-06-01       Impact factor: 4.673

2.  Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.

Authors:  Pooneh Memar Ardestani; Andrew K Evans; Bitna Yi; Tiffany Nguyen; Laurence Coutellier; Mehrdad Shamloo
Journal:  Neuropharmacology       Date:  2017-01-13       Impact factor: 5.250

3.  Verapamil Inhibits Ser202/Thr205 Phosphorylation of Tau by Blocking TXNIP/ROS/p38 MAPK Pathway.

Authors:  Mariarosa Anna Beatrice Melone; Clemente Dato; Simona Paladino; Cinzia Coppola; Claudia Trebini; Maria Teresa Giordana; Lorena Perrone
Journal:  Pharm Res       Date:  2018-02-05       Impact factor: 4.200

Review 4.  Translational Assays for Assessment of Cognition in Rodent Models of Alzheimer's Disease and Dementia.

Authors:  A Shepherd; S Tyebji; A J Hannan; E L Burrows
Journal:  J Mol Neurosci       Date:  2016-09-16       Impact factor: 3.444

Review 5.  Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease.

Authors:  Mak Adam Daulatzai
Journal:  J Neural Transm (Vienna)       Date:  2015-05-06       Impact factor: 3.575

Review 6.  Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Santiago Rivera; Laura García-González; Michel Khrestchatisky; Kévin Baranger
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

7.  Enhanced defense against ferroptosis ameliorates cognitive impairment and reduces neurodegeneration in 5xFAD mice.

Authors:  Liuji Chen; Nawab John Dar; Ren Na; Kirsten Danae McLane; Kwangsun Yoo; Xianlin Han; Qitao Ran
Journal:  Free Radic Biol Med       Date:  2022-01-06       Impact factor: 7.376

8.  Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.

Authors:  Andreea L Turcu; Júlia Companys-Alemany; Matthew B Phillips; Dhilon S Patel; Christian Griñán-Ferré; M Isabel Loza; José M Brea; Belén Pérez; David Soto; Francesc X Sureda; Maria G Kurnikova; Jon W Johnson; Mercè Pallàs; Santiago Vázquez
Journal:  Eur J Med Chem       Date:  2022-04-08       Impact factor: 7.088

9.  Donecopride, a Swiss army knife with potential against Alzheimer's disease.

Authors:  Christophe Rochais; Cédric Lecoutey; Katia Hamidouche; Patrizia Giannoni; Florence Gaven; Eleazere Cem; Serge Mignani; Kevin Baranger; Thomas Freret; Joël Bockaert; Santiago Rivera; Michel Boulouard; Patrick Dallemagne; Sylvie Claeysen
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

10.  LC3-Associated Endocytosis Facilitates β-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer's Disease.

Authors:  Bradlee L Heckmann; Brett J W Teubner; Bart Tummers; Emilio Boada-Romero; Lacie Harris; Mao Yang; Clifford S Guy; Stanislav S Zakharenko; Douglas R Green
Journal:  Cell       Date:  2019-06-27       Impact factor: 66.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.